Streptococcus pyogene antigens
The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. pyogenes , methods for isolating such antigens and specific uses therefore.
1. An isolated S. pyogenes polypeptide consisting of amino acids 31-345 of SEQ ID NO: 215.
2. A fusion protein comprising an isolated polypeptide according to claim 1 and a heterologous peptide consisting of 1 to 10 amino acids.
3. The fusion protein of claim 2 , wherein the peptide consists of 5 to 10 amino acids.
4. The fusion protein of claim 2 , wherein the peptide consists of 1 to 5 amino acids.
5. The fusion protein of claim 2 , wherein the peptide consists of 1 to 3 amino acids.
6. The fusion protein of claim 2 , wherein the peptide consists of 1 to 2 amino acids.
7. A composition comprising:
a) an isolated S. pyogenes polypeptide consisting of amino acids 31-345 of SEQ ID NO: 215; and
b) a pharmaceutically acceptable carrier or excipient.
8. A composition comprising:
a) a fusion protein according to claims 2 , 3 , 4 , 5 , or 6 ; and
b) a pharmaceutically acceptable carrier or excipient.
9. An isolated S. pyogenes polypeptide consisting of amino acids 247-260, 9-33, 41-48, 57-79, 97-103, 113-138, 146-157, 165-186, 195-201, 209-215, 223-229, 237-247, 277-286, 290-297, or 328-342 of SEQ ID NO: 215.
10. A fusion protein comprising an isolated polypeptide according to claim 9 and a heterologous peptide consisting of 1 to 10 amino acids.
11. The fusion protein of claim 10 , wherein the peptide consists of 5 to 10 amino acids.
12. The fusion protein of claim 10 , wherein the peptide consists of 1 to 5 amino acids.
13. The fusion protein of claim 10 , wherein the peptide consists of 1 to 3 amino acids.
14. The fusion protein of claim 10 , wherein the peptide consists of 1 to 2 amino acids.
15. An immunogenic composition comprising:
a) an isolated S. pyogenes polypeptide consisting of amino acids 247-260, 9-33, 41-48, 57-79, 97-103, 113-138, 146-157, 165-186, 195-201, 209-215, 223-229, 237-247, 277-286, 290-297, or 328-342 of SEQ ID NO: 215; and
b) a pharmaceutically acceptable carrier or excipient.
16. An immunogenic composition comprising:
a) a fusion protein according to claims 10 , 11 , 12 , 13 , or 14 ; and
b) a pharmaceutically acceptable carrier or excipient.